• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Schizophrenia (update)

Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update)

Status:	History
Publication date:	March 2009
Wave:	R
Process:	CG
Topic area: Mental health and behavioural conditions

Project team | Schedule | Project history | Key documents

 

NICE project team

Centre for clinical practice lead:	Peter Littlejohns
Communications manager:	Sarita Tamber
Guidelines commissioning manager:	Claire Turner
Guidelines coordinator:	Marietta Smith
Patient involvement lead:	Victoria Thomas
Lead collaborating centre:	National Collaborating Centre for Mental Health
Guidance developer contact:	Esther Flanagan
Guidelines Development Group:	The Guideline Development Group (GDG) oversees the development process.

Top

Email enquiries

If you have any queries please email nice@nice.org.uk

Top

 

Provisional schedule

Scoping workshop:	18 April 2007
Consultation on draft scope with stakeholders:	9 April - 7 May 2007
Consultation on draft guideline with stakeholders:	23 September - 17 November 08
Pre-publication check:	TBC
Publication date:	March 2009

Top

 

Project history

Date Update 26 July 2007 The Guideline Development Group (GDG) oversees the development process. See below for a list of GDG members. The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4 weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG. 21 December 2007 The scope (see link below) defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table (see link below). 23 January 2008 Schedule updated. 19 February 2008 Guidance development group meeting minutes added 23 September 2008 The consultation draft of the guideline is out for consultation with stakeholders. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed below, by the deadline shown. 20 November 2008 Consultation on the draft of the guideline is complete and the guideline is being modified in the light of comments received.

Top

 

Key documents

Schizophrenia (update): comments table responses 25 March 2009 Schizophrenia (update): Guideline consultation 23 September 2008 Schizophrenia (update): Draft full guideline for consultation 23 September 2008 Schizophrenia (update): Draft full guideline - Appendices 22 September 2008 Schizophrenia (update): Draft NICE guideline for consultation 23 September 2008 Schizophrenia (update): Guideline consultation comments proforma 11 November 2008 Schizophrenia (update): list of stakeholders 07 June 2011 Schizophrenia (update: final scope 21 December 2007 Schizophrenia (update): scope consultation table 21 December 2007 Guidance Development Group 19 February 2008 Invitation to health professionals to apply for membership of the schizophrenia guideline development group. 03 April 2007 Invitation to service users/carers to apply for membership of the schizophrenia guideline development group 03 April 2007 Schizophrenia (update): draft scope for consultation 10 April 2007 National Collaborating Centre for Mental Health 02 June 2003 Stakeholder registration 21 April 2004 Developing NICE clinical guidelines 19 April 2004 Chair of the guideline development group - Schizophrenia 07 March 2007 Schizophrenia (update): Draft scope comments form 10 April 2007

This page was last updated: 07 June 2011